Janssen Provides Portfolio Update
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed today that following a review of its portfolio to prioritize the most...
Stay updated with breaking news from Bill Hait. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed today that following a review of its portfolio to prioritize the most...
J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV vaccines in the last month.
J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV vaccines in the last month.
CCO Michael Sneed’s retirement is one of a number of executive changes being made ahead of the planned spinoff of J&J’s consumer division.
The move came a day after Pfizer and BioNTech announced early data suggesting that their booster can offer enhanced protection against the new strain.